SCHEMBL367233

SCHEMBL367233

CN1CCN(c2cc(N3CCN(C(=O)OC(C)(C)C)CC3=O)c3nc(C(=O)NCc4ccc(F)cc4)c(OCc4ccccc4)c(=O)n3c2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.39
TLR9 Q9NR96 3/20 0.38
TLR7 Q9NYK1 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
CYP2C19 P33261 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ENPP2 Q13822 1/20 0.37
ACHE P22303 1/20 0.36
CCNT1 O60563 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CDK9 P50750 1/20 0.36
CCNA1 P78396 1/20 0.36
KIT P10721 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL367968 0.97 TP53 (0.42) TP53TLR9SMN1; SMN2LMNAMAPT
SCHEMBL15092108 0.95 TP53 (0.40) TP53TLR9SMN1; SMN2LMNAMAPT
SCHEMBL368701 0.94 TP53 (0.40) TP53TLR9SMN1; SMN2LMNAMAPT
SCHEMBL10070403 0.92 SMN1; SMN2 (0.39) TP53SMN1; SMN2LMNAMAPTMEN1
SCHEMBL367841 0.90 TP53 (0.39) TP53TLR9TLR7SMN1; SMN2LMNA
SCHEMBL10070053 0.88 SMN1; SMN2 (0.42) TP53SMN1; SMN2LMNAMAPTMEN1
SCHEMBL15092068 0.88 TLR9 (0.43) TLR9TLR7MEN1KMT2AACHE
SCHEMBL367528 0.87 TP53 (0.41) TP53TLR9SMN1; SMN2LMNAMAPT
SCHEMBL368957 0.87 TP53 (0.38) TP53TLR9LMNAMEN1KMT2A
SCHEMBL367788 0.87 LMNA (0.40) TP53SMN1; SMN2LMNAMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130178469-A1 NOVEL ANTIVIRAL AGENTS SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (SIOC) (CN) 2013-07-11 US disclosed
EP-2593460-A1 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS Avexa Limited (AU) 2013-05-22 EP disclosed
WO-2012006680-A1 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS AVEXA LIMITED (AU) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178469-A1 NOVEL ANTIVIRAL AGENTS EIF2AK2, IFNAR1, IRF3 TP53 3404/4885TLR9 177/4885TLR7 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.